Patient tested positive for COVID; This spontaneous case was reported by a non-health professional and describes the occurrence of COVID-19 (Patient tested positive for COVID) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    Previously administered products included for COVID-19 prophylaxis: Moderna (Dose number: 1 , Batch/lot number:014M20A, route of administration: intramuscular.) on 26-Feb-2021, Moderna (Dose number: 2 , Batch/lot number:038A121A and route of administration: intramuscular.) on 26-Mar-2021. Past adverse reactions to the above products included No adverse reaction with Moderna and Moderna.   On 01-Nov-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form On 01-Nov-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. and third dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form. On 29-Jun-2022, the patient experienced COVID-19 (Patient tested positive for COVID). At the time of the report, COVID-19 (Patient tested positive for COVID) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-Jun-2022, SARS-CoV-2 test: positive (Positive) Positive.         No concomitant medication were reported.  It was reported that the patient had not received any other vaccines within 4 weeks prior to the COVID vaccine and patient was never diagnosed with COVID- 19 prior to vaccination.  No treatment medication were reported and no hospitalization prolonged.  Company comment: This spontaneous case concerns a patient (age and gender unspecified) with no medical history reported, who experienced the unexpected non-serious AESI of Covid-19, 1 year 3 months 3 days after receiving the 2nd dose of mRNA-1273 vaccine and 7 months 29 days after receiving TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) as 3rd dose.  SARS-CoV-2 test was positive. The outcome was reported as resolving. Details of symptoms, clinical course, further investigation reports and treatment were not provided. TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) could be a confounder. The current pandemic situation of Covid-19 remains a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a patient (age and gender unspecified) with no medical history reported, who experienced the unexpected non-serious AESI of Covid-19, 1 year 3 months 3 days after receiving the 2nd dose of mRNA-1273 vaccine and 7 months 29 days after receiving TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) as 3rd dose.  SARS-CoV-2 test was positive. The outcome was reported as resolving. Details of symptoms, clinical course, further investigation reports and treatment were not provided. TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) could be a confounder. The current pandemic situation of Covid-19 remains a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.